Foreseeing a Cure for CML
Many patients with CML are now living well while taking powerful medicines that keep the disease in check. Researcher Dr. Michele Baccarani, from Italy, thinks that even a few years of taking medicine could enable some patients to cease therapy and remain in overall good health. For other patients, concern still remains in those who develop resistance to today's approved medicines, cannot tolerate the effects of the medicine or develop the T315i mutation. In this interview from the Controversies in Hematology 2012 in Barcelona, Dr. Baccarani explains his hope for these patients with the use of Ponatinib (AP24534).
Experts & Guests
Michele Baccarani, M.D.
Professor, Institute of Hematology and Oncology, Universita di Bologna in BolognaDr. Michele Baccarani is professor and head of The Institute of Hematology and Oncology at the Universita di Bologna in Bologna, Italy. Dr. Baccarani’s clinical interests include chronic myeloid leukemia, acute leukemia, chemotherapy and stem cell transplantation. His research interests focus on stem cells, multi-drug resistance and molecular pathogenesis of leukemia. more >